Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ...
InvestorsHub on MSN
Johnson & Johnson presents three-year TREMFYA data showing sustained ulcerative colitis outcomes
Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...
Everyday Health on MSN
Crohn’s disease versus ulcerative colitis: What’s the difference?
Crohn’s and UC affect the GI tract differently. Crohn’s impacts the whole tract, while UC is limited to the colon. Learn the ...
Researchers at Örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic ...
Walking is a simple, lower-intensity option that may help reduce stress, which can benefit people with UC. “Lower-impact and ...
Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.
If you find yourself shaking your fists at the sky, demanding to know the truth behind the causes of ulcerative colitis (UC), you’ve probably had your fair share of less-than-pleasant bathroom time.
Stress is an inevitable part of life, but it can impact everyone differently. In patients with ulcerative colitis, stress is a trigger that can lead to flares and worsening symptoms. That means ...
Johnson & Johnson has reported new long‑term results from the QUASAR long‑term extension study, showing that Tremfya (guselkumab) sustained clinical, endoscopic and histologic outcomes through week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results